Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Eyecarrot Innovations

DB:2EYA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2EYA
DB
CA$13M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The last earnings update was 68 days ago. More info.


Add to Portfolio Compare Print
  • Eyecarrot Innovations has significant price volatility in the past 3 months.
2EYA Share Price and Events
7 Day Returns
2.8%
DB:2EYA
16.8%
DE Healthcare Services
2.1%
DE Market
1 Year Returns
-78.4%
DB:2EYA
15.8%
DE Healthcare Services
-16.6%
DE Market
2EYA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eyecarrot Innovations (2EYA) 2.8% -19% -33.5% -78.4% -90.6% -
DE Healthcare Services 16.8% 4.4% -1.9% 15.8% 50.3% 117%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • 2EYA underperformed the Healthcare Services industry which returned 15.8% over the past year.
  • 2EYA underperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
2EYA
Industry
5yr Volatility vs Market

2EYA Value

 Is Eyecarrot Innovations undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Eyecarrot Innovations. This is due to cash flow or dividend data being unavailable. The share price is €0.145.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eyecarrot Innovations's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eyecarrot Innovations's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2EYA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-11-30) in CAD CA$-0.37
TSXV:EYC Share Price ** TSXV (2020-04-07) in CAD CA$0.24
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.51x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eyecarrot Innovations.

DB:2EYA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:EYC Share Price ÷ EPS (both in CAD)

= 0.24 ÷ -0.37

-0.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eyecarrot Innovations is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Eyecarrot Innovations is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Eyecarrot Innovations's expected growth come at a high price?
Raw Data
DB:2EYA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.68x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eyecarrot Innovations, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eyecarrot Innovations's assets?
Raw Data
DB:2EYA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-11-30) in CAD CA$0.08
TSXV:EYC Share Price * TSXV (2020-04-07) in CAD CA$0.24
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.82x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:2EYA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:EYC Share Price ÷ Book Value per Share (both in CAD)

= 0.24 ÷ 0.08

2.84x

* Primary Listing of Eyecarrot Innovations.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eyecarrot Innovations is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Eyecarrot Innovations's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Eyecarrot Innovations has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2EYA Future Performance

 How is Eyecarrot Innovations expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eyecarrot Innovations has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.9%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eyecarrot Innovations expected to grow at an attractive rate?
  • Unable to compare Eyecarrot Innovations's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Eyecarrot Innovations's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Eyecarrot Innovations's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2EYA Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 26.9%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2EYA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2EYA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-11-30 1 -5 -5
2019-08-31 1 -5 -5
2019-05-31 1 -5 -5
2019-02-28 1 -5 -5
2018-11-30 1 -4 -5
2018-08-31 0 -3 -5
2018-05-31 0 -3 -4
2018-02-28 0 -2 -3
2017-11-30 0 -2 -3
2017-08-31 0 -2 -3
2017-05-31 0 -2 -3
2017-02-28 0 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Eyecarrot Innovations is high growth as no earnings estimate data is available.
  • Unable to determine if Eyecarrot Innovations is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2EYA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Eyecarrot Innovations Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2EYA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-11-30 -0.37
2019-08-31 -0.41
2019-05-31 -0.44
2019-02-28 -0.48
2018-11-30 -0.55
2018-08-31 -0.57
2018-05-31 -0.55
2018-02-28 -0.41
2017-11-30 -0.55
2017-08-31 -0.52
2017-05-31 -0.57
2017-02-28 -0.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eyecarrot Innovations will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 2EYA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Eyecarrot Innovations's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Eyecarrot Innovations's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Eyecarrot Innovations's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eyecarrot Innovations has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2EYA Past Performance

  How has Eyecarrot Innovations performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eyecarrot Innovations's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eyecarrot Innovations does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Eyecarrot Innovations's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Eyecarrot Innovations's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Eyecarrot Innovations's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eyecarrot Innovations Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2EYA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-11-30 0.69 -4.68 2.87 0.25
2019-08-31 0.79 -4.82 3.36 0.32
2019-05-31 0.79 -4.84 3.65 0.52
2019-02-28 0.67 -4.77 4.00 0.44
2018-11-30 0.53 -4.92 4.38 0.77
2018-08-31 0.31 -4.55 3.97 0.59
2018-05-31 0.13 -3.95 3.46 0.36
2018-02-28 0.10 -2.71 2.39 0.19
2017-11-30 0.12 -3.44 3.30 0.06
2017-08-31 0.13 -3.15 2.95 0.11
2017-05-31 0.12 -3.33 3.07 0.16
2017-02-28 0.10 -4.34 3.97 0.24
2016-11-30 0.13 -3.56 3.01 0.27
2016-08-31 0.11 -4.05 3.28 0.50
2016-05-31 0.10 -4.71 3.71 0.73
2016-02-29 0.07 -3.84 2.66 0.92
2015-11-30 0.02 -3.28 2.17 1.02
2015-08-31 -2.47 1.68 0.71
2015-05-31 -1.40 0.96 0.38
2015-02-28 -0.87 0.66 0.18
2014-11-30 -0.86 0.60 0.07
2014-08-31 -0.78 0.51 0.07
2014-05-31 -0.74 0.48 0.07
2014-02-28 -0.70 0.43 0.07
2013-11-30 -0.30 0.31
2013-08-31 -0.17 0.14
2013-05-31 -0.09 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Eyecarrot Innovations has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Eyecarrot Innovations has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Eyecarrot Innovations improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Eyecarrot Innovations's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eyecarrot Innovations has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2EYA Health

 How is Eyecarrot Innovations's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eyecarrot Innovations's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eyecarrot Innovations is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eyecarrot Innovations has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eyecarrot Innovations's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 297x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eyecarrot Innovations Company Filings, last reported 4 months ago.

DB:2EYA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-11-30 2.24 0.01 1.35
2019-08-31 1.40 0.03 0.12
2019-05-31 1.98 0.00 0.16
2019-02-28 3.70 0.05 2.16
2018-11-30 4.50 0.00 3.83
2018-08-31 0.90 0.00 0.28
2018-05-31 0.89 0.00 0.02
2018-02-28 1.12 0.00 0.18
2017-11-30 1.84 0.04 0.80
2017-08-31 1.11 0.15 0.02
2017-05-31 1.50 0.00 0.16
2017-02-28 1.96 0.00 0.57
2016-11-30 1.34 0.00 0.06
2016-08-31 1.86 0.00 0.50
2016-05-31 2.43 0.00 0.72
2016-02-29 2.28 0.00 0.57
2015-11-30 3.33 0.00 1.04
2015-08-31 4.42 0.00 2.43
2015-05-31 2.79 0.00 2.76
2015-02-28 -0.27 0.00 0.01
2014-11-30 0.04 0.00 0.29
2014-08-31 -0.16 0.00 0.03
2014-05-31 -0.07 0.00 0.05
2014-02-28 -0.01 0.00 0.06
2013-11-30 0.25 0.00 0.02
2013-08-31 0.41 0.00 0.20
2013-05-31 0.54 0.00 0.34
  • Eyecarrot Innovations's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Eyecarrot Innovations's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Eyecarrot Innovations has less than a year of cash runway based on current free cash flow.
  • Eyecarrot Innovations has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.3% each year.
X
Financial health checks
We assess Eyecarrot Innovations's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eyecarrot Innovations has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2EYA Dividends

 What is Eyecarrot Innovations's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eyecarrot Innovations dividends.
If you bought €2,000 of Eyecarrot Innovations shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eyecarrot Innovations's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eyecarrot Innovations's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2EYA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eyecarrot Innovations has not reported any payouts.
  • Unable to verify if Eyecarrot Innovations's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eyecarrot Innovations's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eyecarrot Innovations has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eyecarrot Innovations's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eyecarrot Innovations afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eyecarrot Innovations has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2EYA Management

 What is the CEO of Eyecarrot Innovations's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adam Cegielski
COMPENSATION CA$120,000
AGE 43
TENURE AS CEO 8.2 years
CEO Bio

Mr. Adam R. Cegielski, B.Sc. serves as Director at RewardStream Solutions Inc. since March 11, 2020. He was the Chief Executive Officer and Director of Essex Minerals Inc. from January 2019 to March 2019. Mr. Cegielski served as Chief Executive Officer of Montego Resources Inc. until April 2019 and was its Director since September 2018. He is a Corporate Secretary at Montego Resources Inc. since March 2019. Mr. Cegielski is a Co-Founder of Eyecarrot Innovations Corp. and has been its Chief Executive Officer and President since February 2012. He has been Chief Product Officer of Eyecarrot Innovations Corp. since July 2015. He has been the Chief Executive Officer and President of Nanton Nickel Corporation since February 29, 2012. Mr. Cegielski has been the Sole Proprietor of Insight Consulting since 1999. He served as Chief Executive Officer, President, Secretary and Executive Director of Resgreen Group International Inc. from April 21, 2006 to May 23, 2008 and served as its Principal Accounting Officer since April 2006. He has experience as a director and senior officer of publicly listed companies. From September 2010 to October 2011, Mr. Cegielski served as Investor Relations consultant for Keegan Resources Inc. a TSX listed gold exploration company. He served as the Chief Executive Officer at Crest Petroleum Corp. until October 15, 2013. Mr. Cegielski served as the Chief Financial Officer and Chief Executive Officer of Cayden Resources Inc. (alternate name Vistech Capital Corp). Mr. Cegielski served as the President, Chief Executive Officer, Secretary and Treasurer of Uranium Hunter Corp. (Formerly Brownsville Company) from April 21, 2006 to May 2008 and also served as its Principal Accounting Officer since April 21, 2006. Mr. Cegielski served as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of GoldMountain Exploration Corporation (Formerly Konigsberg Corp) from March 27, 2006 to March 2008 and served as its Principal Accounting Officer. Mr. Cegielski served as the Acting Chief Financial Officer of IBI Corporation until November 1, 2006. He serves as Director of Seaside Exploration Partners Corp. He has been a Director of Brownsville Co, since April 21, 2006, Konigsberg Corp. since March 27, 2006. He has been a Director of Eyecarrot Innovations Corp. since February 29, 2012. He served as Director of Crest Petroleum Corp since January 24, 2012 until October 2014. He served as a Director of Cayden Resources Inc., since November 10, 2008. He served as Director of Kootenay Zinc Corp. from May 2015 to September 2016. He served as an Executive Director of Uranium Hunter Corporation from March 2006 to May 2008. From March 2006 to January 2008, Mr. Cegielski served as a Director of GoldMountain Exploration Corporation (formerly Konigsberg Corp.) Mr. Cegielski is a graduate of the University of Guelph in Ontario, Canada where he gained his Bachelor of Science and holds Honors degree from the College of Physical and Engineering Science in Applied Biochemistry.

CEO Compensation
  • Adam's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Adam's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Eyecarrot Innovations management team in years:

3.1
Average Tenure
55
Average Age
  • The tenure for the Eyecarrot Innovations management team is about average.
Management Team

Adam Cegielski

TITLE
Founder
COMPENSATION
CA$120K
AGE
43
TENURE
8.2 yrs

Rakesh Malhotra

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$54K
AGE
62
TENURE
1.3 yrs

Sam Mithani

TITLE
CTO & Director
COMPENSATION
CA$275K
AGE
55
TENURE
3.3 yrs

Tania Archer

TITLE
Head of Marketing & Sales
TENURE
1.1 yrs

Selwyn Super

TITLE
Chief Scientific Director
AGE
87

Patrick Quaid

TITLE
Chief Scientific Advisor & Member of Advisory Board
AGE
40

Joe Lia

TITLE
Director of Video Production & Member of Advisory Board
TENURE
4.6 yrs

Leonard Press

TITLE
Director of Global Education & Member of Advisory Board
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Eyecarrot Innovations board of directors in years:

4.8
Average Tenure
43
Average Age
  • The tenure for the Eyecarrot Innovations board of directors is about average.
Board of Directors

Adam Cegielski

TITLE
Founder
COMPENSATION
CA$120K
AGE
43
TENURE
8.2 yrs

Sam Mithani

TITLE
CTO & Director
COMPENSATION
CA$275K
AGE
55
TENURE
3.3 yrs

Patrick Quaid

TITLE
Chief Scientific Advisor & Member of Advisory Board
AGE
40

Joe Lia

TITLE
Director of Video Production & Member of Advisory Board

Leonard Press

TITLE
Director of Global Education & Member of Advisory Board

Todd Finch

TITLE
Head of Advisory Board
AGE
51
TENURE
4.7 yrs

Sean Charland

TITLE
Independent Director
AGE
37
TENURE
8 yrs

John Flanagan

TITLE
Independent Director
TENURE
4.8 yrs

Bryce Salvador

TITLE
Special Advisor of Performance and Athletics

Robert Sanet

TITLE
Special Advisor of Behavioral Optometry & Vision Training
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Dec 19 Sell Salim Mithani Individual 29. Nov 19 29. Nov 19 -100,000 €0.14 €-14,340
11. Oct 19 Sell Adam Cegielski Individual 11. Oct 19 11. Oct 19 -30,000 €0.12 €-3,710
09. Oct 19 Sell Adam Cegielski Individual 19. Sep 19 19. Sep 19 -322,936 €0.12 €-39,687
X
Management checks
We assess Eyecarrot Innovations's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eyecarrot Innovations has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2EYA News

Simply Wall St News

2EYA Company Info

Description

Eyecarrot Innovations Corp. develops and commercializes visual and neuro-cognitive processing products, and hardware and software for diagnosing and remediating visual perception disorders. The company’s products include Binovi Touch, a tool for vision therapy and vision training; Binovi Pro, which allows doctors/trainers to manage various aspects of patient/athlete’s vision training regimens, track progress, and plan and assign protocols; Binovi Coach, a tool that allows users to complete their assigned activities through clear multimedia guidance; and Binovi Academy, an educational hub. The company was formerly known as Nanton Nickel Corp. and changed its name to Eyecarrot Innovations Corp. in June 2015. Eyecarrot Innovations Corp. is based in Oakville, Canada.

Details
Name: Eyecarrot Innovations Corp.
2EYA
Exchange: DB
Founded:
CA$8,630,310
50,781,355
Website: http://www.eyecarrot.com
Address: Eyecarrot Innovations Corp.
482 South Service Road East,
Unit 119,
Oakville,
Ontario, L6J 2X6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV EYC Common Shares TSX Venture Exchange CA CAD 29. Aug 2012
OTCPK EYCC.F Common Shares Pink Sheets LLC US USD 29. Aug 2012
DB 2EYA Common Shares Deutsche Boerse AG DE EUR 29. Aug 2012
Number of employees
Current staff
Staff numbers
0
Eyecarrot Innovations employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 22:26
End of day share price update: 2020/04/07 00:00
Last earnings filing: 2020/01/30
Last earnings reported: 2019/11/30
Last annual earnings reported: 2019/02/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.